[February 19, 2018]

Mircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) Drug Analysis 2018 - ResearchAndMarkets.com

The "Drug Analysis: Mircera" drug pipelines has been added to ResearchAndMarkets.com's offering.

Mircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator.

The drug was originally available in Europe and Japan, and launched in the US in late 2015. It has the potential to overtake the current market leader Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) in the anemia in chronic kidney disease market, on account of its superior dosing interval and cost efficiency.

However, the drug still leaves significant unmet needs due to serious safety concerns. Clinical trials demonstrating these concerns have caused health agencies to issue strict guidelines rearding doses and use of ESAs, which have reduced ESA use and are likely to affect Mircera's future uptake.

Mircera is administered by intravenous or subcutaneous injection, and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow.

Key Topics Covered:

List of Figures

Figure 1: Mircera for anemia in chronic kidney disease - SWOT analysis

Figure 2: Drug assessment summary of Mircera for anemia in chronic kidney disease

Figure 3: Drug assessment summary of Mircera for anemia in chronic kidney disease

Figure 4: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24

List of Tables

Table 1: Mircera drug profile

Table 2: Mircera pivotal trial data in anemia in chronic kidney disease

Table 3: Mircera late-phase trial data in anemia in chronic kidney disease

Table 4: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zwtrsz/mircera_methoxy?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180219005525/en/

[ Back To TMCnet.com's Homepage ]